Shop
Crizotinib (brand name: Xalkori, Sekuri; Incepta).
Original price was: £379.00.£249.00Current price is: £249.00.Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer in the United States. It has demonstrated significant clinical efficacy in patients with tumors characterized by abnormal ALK, ROS1, and MET kinase activity.
MedFind provides access to Crizotinib through verified overseas procurement channels, with guaranteed authenticity, in-stock availability, rapid shipping, full logistics tracking, and privacy-protected handling. Professional guidance is available upon inquiry, including information on indications, clinical efficacy, adverse effects, and medication usage instructions.
Ibrutinib / Ibrutinib Capsules / Imbruvica (Everest)
Original price was: £300.00.£249.00Current price is: £249.00.Ibrutinib (Brand name: Imbruvica) is an oral BTK inhibitor used for the treatment of relapsed mantle cell lymphoma (MCL), relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia (WM).
MedFind provides overseas sourcing services for Ibrutinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Cabozantinib (Everest)
Original price was: £299.00.£245.00Current price is: £245.00.Cabozantinib manufactured by Everest Pharma is a multi-target broad-spectrum anticancer therapy that has demonstrated promising clinical efficacy across a wide range of solid tumors.
Cabozantinib has shown beneficial treatment effects in:
- Renal cell carcinoma (kidney cancer)
- Thyroid cancer
- Liver cancer
- Soft tissue sarcoma
- Non-small cell lung cancer (NSCLC)
- Prostate cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
and several other advanced malignancies.
Cabozantinib is particularly recognized for its strong effectiveness in controlling bone metastases, helping reduce tumor progression and complications associated with metastatic bone disease.
Due to its broad antitumor activity across multiple cancer types, Cabozantinib is often referred to as a “multi-purpose” or “broad-spectrum” targeted therapy among tyrosine kinase inhibitors (TKIs).
Niraparib / Zejula (Everest)
Original price was: £344.00.£244.00Current price is: £244.00.Niraparib (also known as Niraparib; Brand name: Zejula) is a PARP inhibitor used for maintenance treatment of advanced recurrent ovarian cancer.
Niraparib has been shown to significantly prolong progression-free survival and help reduce the risk of ovarian cancer recurrence in patients with advanced disease.
MedFind provides overseas sourcing services for Niraparib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, side effects, and medication guidance.
Ibrutinib (also translated as Yilutini; brand name: Yike; Incepta).
Original price was: £399.00.£238.00Current price is: £238.00.Ibrutinib produced by Incepta (generic name: Ibrutinib, also translated as Yilutini; brand names: Imbruvica, Yike) is an oral Bruton’s tyrosine kinase (BTK) inhibitor. It exerts its antitumor effect by inhibiting BTK, which is required for tumor cell proliferation and metastasis.
It is used for the treatment of relapsed mantle cell lymphoma, relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia.
Alectinib (Anshengsha, Everest)
Original price was: £370.00.£194.00Current price is: £194.00.Alectinib produced by Everest (also translated as Ailetinib or Alectinib; brand name: Alecensa/Anshengsha) is a second-generation ALK inhibitor developed by the U.S. pharmaceutical company Roche.
Alectinib was first approved by the U.S. FDA in December 2015 for the treatment of non-small cell lung cancer (NSCLC) patients who had developed resistance to crizotinib. In November 2017, it was further approved for first-line treatment of advanced ALK-positive NSCLC.
Avatrombopag (Everest)
Original price was: £208.00.£182.00Current price is: £182.00.Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate bone marrow platelet production and help reduce the risk of bleeding caused by thrombocytopenia.
MedFind provides overseas sourcing services for Avatrombopag through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Supports platelet recovery for patients with low platelet counts before surgery and those with chronic immune thrombocytopenia (ITP), with product authenticity assurance, fast shipment availability, and professional consultation support.
Osimertinib (brand name: Tagrisso, Terisha; Incepta).
Original price was: £288.00.£97.00Current price is: £97.00.由 Incepta 公司生产的奥希替尼是一种第三代口服不可逆 EGFR 靶向酪氨酸激酶抑制剂 (EGFR-TKI)，由英国阿斯利康公司开发。其原商品名为泰瑞沙 (Tagrisso)，研发代号为 AZD9291。
它用于治疗晚期非小细胞肺癌（NSCLC），并选择性地抑制 EGFR 敏感突变和 EGFR T790M 耐药突变。
Osimertinib / Tagrisso (Everest)
Original price was: £108.00.£91.00Current price is: £91.00.Osimertinib (Brand name: Tagrisso) is a third-generation oral, irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) originally developed by AstraZeneca under the research code AZD9291.
It is used for the treatment of advanced non-small cell lung cancer (NSCLC) and selectively targets both EGFR-sensitive mutations and the EGFR T790M resistance mutation.
Osimertinib (Tagrisso) received approval for import and clinical use in China in March 2017.
